Switch theme
Sign up to access all valuation multiples
Vetoquinol SA operates is a France-based firm serving in the healthcare market. Its focus lies on developing and marketing veterinary drugs mainly in the European region and to a certain extent in America and Asia. Its portfolio of drugs entails anti-infectives, anti- pain inflammatory drugs, cardiovascular and nephrology treatment intended mainly for pets and livestock.
1933
2.1K+
LTM Revenue $585M
LTM EBITDA $115M
$811M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vetoquinol has a last 12-month revenue of $585M and a last 12-month EBITDA of $115M.
In the most recent fiscal year, Vetoquinol achieved revenue of $568M and an EBITDA of $121M.
Vetoquinol expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vetoquinol valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $580M | $568M | XXX | XXX | XXX |
| Gross Profit | $398M | $408M | XXX | XXX | XXX |
| Gross Margin | 69% | 72% | XXX | XXX | XXX |
| EBITDA | $113M | $121M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 21% | XXX | XXX | XXX |
| Net Profit | $67.5M | $51.6M | XXX | XXX | XXX |
| Net Margin | 12% | 9% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vetoquinol's stock price is EUR 76 (or $82).
Vetoquinol has current market cap of EUR 903M (or $970M), and EV of EUR 755M (or $811M).
See Vetoquinol trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $811M | $970M | XXX | XXX | XXX | XXX | $5.49 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vetoquinol has market cap of $970M and EV of $811M.
Vetoquinol's trades at 1.4x LTM EV/Revenue multiple, and 7.0x LTM EBITDA.
Analysts estimate Vetoquinol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vetoquinol and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $811M | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | XXX | XXX |
| P/E | 16.2x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | 10.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVetoquinol's NTM/LTM revenue growth is 4%
Vetoquinol's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Vetoquinol's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vetoquinol's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vetoquinol and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 14% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 56% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Mad Paws | XXX | XXX | XXX | XXX | XXX | XXX |
| i-Tail | XXX | XXX | XXX | XXX | XXX | XXX |
| Central Garden & Pet | XXX | XXX | XXX | XXX | XXX | XXX |
| Dogness | XXX | XXX | XXX | XXX | XXX | XXX |
| Freshpet | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vetoquinol acquired XXX companies to date.
Last acquisition by Vetoquinol was XXXXXXXX, XXXXX XXXXX XXXXXX . Vetoquinol acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vetoquinol founded? | Vetoquinol was founded in 1933. |
| Where is Vetoquinol headquartered? | Vetoquinol is headquartered in France. |
| How many employees does Vetoquinol have? | As of today, Vetoquinol has 2.1K+ employees. |
| Who is the CEO of Vetoquinol? | Vetoquinol's CEO is Mr. Matthieu Frechin. |
| Is Vetoquinol publicy listed? | Yes, Vetoquinol is a public company listed on PAR. |
| What is the stock symbol of Vetoquinol? | Vetoquinol trades under VETO ticker. |
| When did Vetoquinol go public? | Vetoquinol went public in 2006. |
| Who are competitors of Vetoquinol? | Similar companies to Vetoquinol include e.g. Mad Paws, i-Tail, Central Garden & Pet, Dogness. |
| What is the current market cap of Vetoquinol? | Vetoquinol's current market cap is $970M |
| What is the current revenue of Vetoquinol? | Vetoquinol's last 12-month revenue is $585M. |
| What is the current EBITDA of Vetoquinol? | Vetoquinol's last 12-month EBITDA is $115M. |
| What is the current EV/Revenue multiple of Vetoquinol? | Current revenue multiple of Vetoquinol is 1.4x. |
| What is the current EV/EBITDA multiple of Vetoquinol? | Current EBITDA multiple of Vetoquinol is 7.0x. |
| What is the current revenue growth of Vetoquinol? | Vetoquinol revenue growth between 2023 and 2024 was -2%. |
| Is Vetoquinol profitable? | Yes, Vetoquinol is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
